Valeant Closes $8.7B Buy of PE-Backed Bausch + Lomb
Montréal-based Valeant Pharmaceuticals International Inc. (NYSE: VRX and TSX: VRX) has completed its acquisition of eye care specialist Bausch + Lomb Holdings Inc. from U.S. private equity firm Warburg Pincus, which acquired the Rochester, New York-based company in 2007. Valeant in May agreed to pay US$8.7 billion in cash, of which around US$4.5 billion would go to Warburg Pincus and other investors, and around US$4.2 billion would be used to repay Bausch + Lomb's debt.
8 August 2013•1 min read
